Literature DB >> 12752217

Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas.

Nam Jin Yoo1, Hong Sug Kim, Su Young Kim, Won Sang Park, Cho Hyun Park, Hae Myung Jeon, Eun Sun Jung, Jung Young Lee, Sug Hyung Lee.   

Abstract

Second mitochondria-derived activator of caspases (Smac/DIABLO) is released from mitochondria into the cytosol during apoptosis, promoting caspase activation by neutralizing the inhibition of inhibitor of apoptosis proteins (IAPs) on caspases. Alteration of apoptosis is essential for cancer development, and cancer cell death by radiation and chemotherapy is largely dependent upon apoptosis. In this study, archival tissues of 100 carcinomas and 50 sarcomas from various origins were analyzed by immunohistochemistry for the expression of Smac/DIABLO. Smac/DIABLO immunoreactivity was seen in 62 of 100 (62%) carcinomas, including 42 of 60 stomach carcinomas, 7 of 10 colorectal carcinomas, 4 of 10 lung carcinomas, 7 of 10 ovarian carcinomas, and 2 of 10 prostate carcinomas. Smac/DIABLO is expressed in 11 of 50 (22%) sarcomas, including 2 of 8 malignant schwannomas, 5 of 11 rhabdomyosarcomas, 2 of 7 malignant fibrous histiocytomas, 1 of 6 leiomyosarcomas, 0 of 8 angiosarcomas, 0 of 8 liposarcomas, and 1 of 2 Ewing's sarcomas. These data demonstrated that Smac/DIABLO expression levels vary depending on the individual cancer types. Furthermore, the present study showed that many human cancers do not express Smac/DIABLO, and suggest that lack of Smac/DIABLO expression in the cancer cells may inhibit apoptosis, thereby promoting their survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12752217     DOI: 10.1034/j.1600-0463.2003.t01-1-1110202.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  15 in total

1.  Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer.

Authors:  A Mansour; M Nabil; R Ali-Labib; H Said; F Annos
Journal:  Med Oncol       Date:  2011-12-08       Impact factor: 3.064

2.  Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.

Authors:  Xiaoyong Hu; Xiaochun Chen; Hao Ping; Zhaohui Chen; Fuqing Zeng; Gongcheng Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Dysregulated Expression of Apoptosis-Associated Genes and MicroRNAs and Their Involvement in Gastric Carcinogenesis.

Authors:  Mayara Luciana Sallas; Diana Zapparoli; Mônica Pezenatto Dos Santos; Jéssica Nunes Pereira; Wilson Aparecido Orcini; Rita Luiza Peruquetti; Elizabeth Suchi Chen; Marilia de Arruda Cardoso Smith; Spencer Luiz Marques Payão; Lucas Trevizani Rasmussen
Journal:  J Gastrointest Cancer       Date:  2021-06

4.  A New Role for the Mitochondrial Pro-apoptotic Protein SMAC/Diablo in Phospholipid Synthesis Associated with Tumorigenesis.

Authors:  Avijit Paul; Yakov Krelin; Tasleem Arif; Rina Jeger; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2017-12-24       Impact factor: 11.454

5.  Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value.

Authors:  Carsten Kempkensteffen; Stefan Hinz; Frank Christoph; Hans Krause; Ahmed Magheli; Mark Schrader; Martin Schostak; Kurt Miller; Steffen Weikert
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-09       Impact factor: 4.553

6.  X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma.

Authors:  Yutao Zhang; Jianhua Zhu; Yun Tang; Feng Li; Hongyuan Zhou; Bofang Peng; Chifeng Zhou; Rong Fu
Journal:  Diagn Pathol       Date:  2011-06-07       Impact factor: 2.644

7.  High Smac/DIABLO expression is associated with early local recurrence of cervical cancer.

Authors:  Abril Arellano-Llamas; Francisco J Garcia; Delia Perez; David Cantu; Magali Espinosa; Jaime G De la Garza; Vilma Maldonado; Jorge Melendez-Zajgla
Journal:  BMC Cancer       Date:  2006-10-26       Impact factor: 4.430

8.  Targeted therapy in Ewing sarcoma.

Authors:  A Lissat; M M Chao; U Kontny
Journal:  ISRN Oncol       Date:  2012-05-28

Review 9.  Progress in gene therapy using oncolytic vaccinia virus as vectors.

Authors:  Xue Yang; Biao Huang; Lili Deng; Zhigang Hu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-06       Impact factor: 4.322

10.  Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas.

Authors:  Y Yan; C Mahotka; S Heikaus; T Shibata; N Wethkamp; J Liebmann; C V Suschek; Y Guo; H E Gabbert; C D Gerharz; U Ramp
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.